Synthorx, Inc. focuses on prolonging and improving lives of cancer and autoimmune disorder patients. Its product pipeline is comprised of THOR-707, IL-2 Synthorin, IL-10 Synthorin, and IL-15 Synthorin. The company was founded by Floyd E. Romesberg and Court R. Turner in 2014 and is headquartered in La Jolla, CA.
Company profile
Website
CEO
Laura K. Shawver
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
464709185
Latest filings (excl ownership)
SEC STAFF
SEC staff action: Order
18 Feb 20
SEC STAFF
SEC staff action: Order
10 Feb 20
15-12B
Securities registration termination
3 Feb 20
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jan 20
8-K
Completion of Acquisition or Disposition of Assets
23 Jan 20
25-NSE
Exchange delisting
23 Jan 20
SC TO-T/A
Third party tender offer statement (amended)
23 Jan 20
SC 14D9/A
Tender offer solicitation (amended)
23 Jan 20
SC TO-T/A
Third party tender offer statement (amended)
21 Jan 20
Latest ownership filings
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Synthorx, Inc.
7 Feb 20
4
Peter A. Thompson
24 Jan 20
4
Laura Shawver
24 Jan 20
4
Pratik Shah
24 Jan 20
4
Tighe Reardon
24 Jan 20
4
Andrew Kenneth William Powell
24 Jan 20
4
Marcos Milla
24 Jan 20
4
Jay Lichter
24 Jan 20
4
Joseph Leveque
24 Jan 20
Institutional ownership, Q1 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|